Bile Duct Tumors: Causes, Symptoms, Diagnosis and Treatment — Overview, Diagnosis & Treatment Options | MyMedicPlus

Bile duct tumors — collectively referred to as cholangiocarcinoma (CCA) — are malignant neoplasms arising from the epithelial lining (cholangiocytes) of the intra- or extrahepatic biliary tree. They represent approximately 15% of all hepatobiliary malignancies worldwide and are the second most common primary liver malignancy after hepatocellular carcinoma. Three anatomical subtypes are recognized: intrahepatic CCA (iCCA, approximately 20% — hepatic parenchyma, typically presents as a mass), perihilar CCA (pCCA, approximately 50% — Klatskin tumor, at the confluence of the right and left hepatic ducts, classified by Bismuth-Corlette staging I-IVb based on ductal involvement), and distal extrahepatic CCA (dCCA, approximately 30% — below the cystic duct, typically requires pancreaticoduodenectomy). The global incidence of iCCA is rising at approximately 2-3% annually, in parallel with increasing rates of non-alcoholic fatty liver disease and hepatitis C in Western populations. The majority of patients present with unresectable or metastatic disease; only approximately 20-30% of all CCA patients undergo surgical resection with curative intent. The genomic landscape of CCA, particularly iCCA, is remarkably actionable compared to most gastrointestinal cancers — FGFR2 fusions (~15% iCCA), IDH1 mutations (~20% iCCA), NTRK fusions, RET fusions, HER2 amplification, and MSI-H status each define molecularly defined subgroups with approved targeted therapies, making comprehensive NGS profiling essential at diagnosis. The TOPAZ-1 trial (2022) established gemcitabine plus cisplatin plus durvalumab (anti-PD-L1 checkpoint inhibitor) as the first-line treatment standard for advanced biliary tract cancer, achieving median OS of 12.8 months.

Risk factors for CCA vary significantly by anatomical subtype and geographic region. Primary sclerosing cholangitis (PSC): causes chronic fibrosing biliary inflammation and progressive biliary strictures; PSC patients face a 10-15% lifetime CCA risk, with CCA developing at a median age approximately 30 years younger than sporadic CCA; annual surveillance with MRCP and CA 19-9 is recommended but imperfect, as PSC-related strictures obscure CCA on imaging. Liver fluke infection: Opisthorchis viverrini (northeastern Thailand, Laos) and Clonorchis sinensis (China, Korea, Vietnam) infect the biliary tree after ingestion of undercooked freshwater fish; mechanical irritation of biliary epithelium by flukes plus their pro-inflammatory excretory-secretory products drive prolonged biliary carcinogenesis — the principal CCA risk factor in Asia; CCA incidence in high-endemicity regions may exceed 85 per 100,000. Biliary structural anomalies: choledochal cysts (types I-V) carry a lifetime CCA risk of up to 20%, most commonly in the Type I and IV variants — prophylactic resection is recommended; Caroli disease (Type V, congenital intrahepatic duct ectasia); hepatolithiasis (intrahepatic stones); biliary-enteric anastomosis with chronic reflux. Chronic liver disease: HBV infection (2-3 fold elevated iCCA risk), HCV infection (2-3 fold), alcohol-related cirrhosis, and NAFLD/NASH-related cirrhosis all contribute to iCCA risk through chronic hepatic inflammation, oxidative stress, and cellular turnover. Molecular oncogenesis in sporadic CCA: FGFR2 fusions (BICC1, AHCYL1, TACC3 fusion partners — approximately 15-20% of iCCA, rare in pCCA and dCCA); IDH1 mutation (R132 codon — approximately 15-20% iCCA); KRAS/NRAS mutations (approximately 20-45% pCCA and dCCA, less common in iCCA); BRAF V600E (approximately 5%); TP53 mutations; ARID1A (SWI/SNF complex chromatin remodeling); BRCA1/2 germline mutations (5-8%); HER2 amplification (approximately 5-10% extrahepatic CCA); NTRK/RET/MET fusions (2-5% each). Lynch syndrome (MMR gene mutations) accounts for approximately 10% of MSI-H CCA cases.

The clinical presentation of bile duct tumors varies markedly by anatomical subtype. Perihilar CCA (most common): painless, progressive obstructive jaundice — the classical presentation — with deepening scleral icterus and skin yellowing over days to weeks, dark tea-colored urine (bilirubinuria), acholic pale stools (absent urobilinogen), and severe generalized pruritus from cutaneous bile salt deposition; mild RUQ discomfort or pressure may accompany jaundice. Distal CCA: closely resembles ampullary or pancreatic head cancer — painless obstructive jaundice, pale stools, dark urine; Courvoisier's sign (palpable non-tender distended gallbladder with jaundice, seen in approximately 25%). Intrahepatic CCA: characteristically asymptomatic until large — most commonly discovered incidentally on abdominal CT or ultrasound as a hepatic mass; hepatomegaly, right upper quadrant or epigastric discomfort, and weight loss in symptomatic cases; rarely presents with obstructive jaundice unless central biliary ducts are involved. Cholangitis (complication): Charcot's triad (episodic fever with rigors, jaundice, and RUQ pain) from secondary bacterial infection of obstructed bile — a medical emergency requiring urgent biliary decompression and antibiotics (Reynold's pentad adds shock and mental status changes indicating ascending cholangitis). Systemic features of advanced or metastatic disease: significant unintentional weight loss (>10% body weight), pronounced fatigue, progressive anorexia, muscle wasting, and low-grade fever. Peritoneal carcinomatosis: ascites, nausea, and abdominal distension. Portal vein thrombosis from tumor involvement: portal hypertension, variceal bleeding, and worsening ascites. CA 19-9 levels above 100 U/mL in a PSC patient are highly specific for superimposed CCA.

Multiphase contrast-enhanced CT abdomen/chest with hepatobiliary protocol: primary staging investigation — characterizes tumor morphology (iCCA appears as hypovascular hepatic mass with arterial rim enhancement and delayed central enhancement; pCCA appears as periductal enhancing lesion causing proximal biliary dilation; dCCA produces focally dilated bile duct with obstructing mass). MRI liver with gadoxetic acid (Primovist/Eovist) plus MRCP: superior hepatic lesion characterization and biliary anatomy — optimal for hepatectomy planning; MRCP provides 3D bile duct roadmap essential for Bismuth-Corlette staging in pCCA. ERCP with biliary brushings: cytological diagnosis from biliary stricture brushings alone has sensitivity of approximately 25-40%; combined with FISH for chromosomal aneusomy improves sensitivity to approximately 55-65%; facilitates biliary stenting for jaundice relief. EUS with FNA: for distal CCA and lymph node sampling; for iCCA, CT-guided core needle biopsy is preferred. Serum CA 19-9: elevated (above 37 U/mL) in approximately 75% of CCA; levels above 100 U/mL in PSC have high specificity; falsely normal in Lewis antigen-negative individuals (approximately 10% of population); falsely elevated in benign biliary disease and cholangitis. CEA: less sensitive (~30%), useful in combination with CA 19-9. FDG-PET-CT: detects occult nodal and distant metastases; particularly useful for PSC-related CCA and for ruling out metastatic disease before major hepatectomy or liver transplant listing. AJCC 8th edition TNM staging: different staging classifications for iCCA vs pCCA vs dCCA; Bismuth-Corlette classification I-IVb for pCCA extent. Comprehensive NGS molecular profiling: RNA-based NGS preferred to detect FGFR2 fusions (DNA-based NGS may miss fusions if not designed for intronic breakpoints); IDH1/IDH2 mutation by DNA sequencing; KRAS/NRAS/BRAF exons 2-4; NTRK1/2/3 fusion by RNA or DNA; HER2 amplification by FISH or NGS; MSI/dMMR status by IHC and/or PCR; TMB by NGS; RET and MET alterations.

Complete surgical resection (R0) is the only treatment with curative potential and is feasible in approximately 20-30% of patients at diagnosis. Intrahepatic CCA: anatomical hepatic resection (segmentectomy or major hepatectomy guided by tumor location, portal vein distribution, and FLR adequacy); portal vein embolization of the future liver remnant when FLR below 25-30% to induce contralateral hepatic hypertrophy before major resection; adjuvant capecitabine 1250 mg/m2 BD on days 1-14 of each 21-day cycle for 6 months improves OS versus observation (BILCAP trial: OS HR 0.75). Perihilar CCA: the most surgically demanding CCA — requires extended hepatectomy (right or left trisectionectomy) including caudate lobe resection plus extrahepatic bile duct resection and hepaticojejunostomy reconstruction; liver transplantation for select unresectable pCCA (Mayo protocol: neoadjuvant chemoradiation with capecitabine plus intensity-modulated RT with 45 Gy plus brachytherapy boost, followed by staging laparoscopy before transplant listing) achieves 5-year OS of approximately 65-70%. Distal CCA: pancreaticoduodenectomy (Whipple procedure); adjuvant capecitabine. Biliary stenting: SEMS for biliary palliation in unresectable disease; plastic biliary stents for preoperative drainage. First-line systemic treatment for advanced biliary tract cancer: gemcitabine 1000 mg/m2 IV plus cisplatin 25 mg/m2 IV on days 1 and 8, every 21 days, plus durvalumab 1500 mg IV on day 1 (TOPAZ-1 trial: median OS 12.8 months, 24-month OS 24.9% — now the international standard). Molecularly targeted second-line therapy: FGFR2 fusion-positive iCCA — pemigatinib 13.5 mg orally once daily on a 21/7-day schedule (FIGHT-202: ORR 35.5%, mPFS 6.9 months) or futibatinib 20 mg orally once daily continuous dosing (FOENIX-CCA2: ORR 41.7%); IDH1-mutated — ivosidenib 500 mg orally once daily (ClarIDHy: OS 10.3 vs 7.5 months vs placebo); MSI-H/dMMR — pembrolizumab 200 mg every 3 weeks; NTRK fusion — larotrectinib or entrectinib; HER2 amplification/overexpression — trastuzumab-based or trastuzumab deruxtecan (T-DXd); RET fusion — selpercatinib. Locoregional therapies for unresectable iCCA: transarterial chemoembolization (TACE), transarterial radioembolization (TARE with 90Y microspheres), ablation (RFA, microwave), and stereotactic body radiotherapy (SBRT) — all used in select patients with liver-only disease.

Bile duct tumors (cholangiocarcinoma) carry a generally poor prognosis, predominantly because most patients present with locally advanced or metastatic disease not amenable to curative surgical resection. For the minority (approximately 20-30%) who undergo curative-intent hepatic resection or Whipple procedure, 5-year overall survival is approximately 25-40% depending on margin status, nodal involvement, and CCA subtype. Perihilar CCA liver transplantation meeting Mayo protocol criteria achieves 5-year OS of approximately 65-70% in carefully selected patients — the best long-term outcomes currently achievable for cholangiocarcinoma. For advanced or metastatic biliary tract cancer treated with gemcitabine plus cisplatin plus durvalumab, median overall survival is approximately 12.8 months (TOPAZ-1 trial), representing the current first-line standard. Targeted therapies for actionable molecular alterations extend survival further: FGFR2 fusion-positive iCCA treated with pemigatinib or futibatinib achieves median OS of approximately 18-22 months; IDH1-mutated CCA treated with ivosidenib achieves median OS of approximately 10 months versus 5.1 months for placebo. MSI-H CCA responds durably to pembrolizumab with objective responses in approximately 40-50% of patients. By stage: resectable CCA achieves 5-year survival of 25-40%; locally advanced unresectable CCA has median OS of approximately 8-12 months with locoregional therapy; metastatic disease achieves median OS of approximately 12-14 months with modern systemic therapy combinations. Recurrence after curative resection occurs in approximately 60-70% of patients within 3 years, predominantly in the liver, peritoneum, and lymph nodes. Prognostic factors include R0 resection margin, lymph node status, preoperative CA 19-9 elevation, and presence of actionable molecular alterations. Long-term quality of life is often maintained with modern biliary stenting and systemic therapy management.

PSC patients require systematic semi-annual surveillance with MRI/MRCP and serum CA 19-9 — incidentally detected early CCA may be resectable with curative intent, whereas symptomatic CCA is rarely resectable. In Southeast Asia, population-level praziquantel treatment campaigns, health education regarding avoidance of raw freshwater fish (the source of liver fluke infection), and improved sanitation infrastructure reduce the liver fluke-driven CCA burden. HBV vaccination and treatment of chronic hepatitis B and C reduce cirrhosis and associated CCA risk. Prophylactic resection of choledochal cysts is recommended as these confer substantial CCA risk. Complete NGS molecular profiling at diagnosis is essential to ensure access to all targeted therapy options and maximise survival. Adequate treatment of hepatolithiasis (intrahepatic bile duct stones) reduces associated chronic biliary inflammation.

Painless, progressive jaundice — yellowing of the skin and eyes, dark urine, pale stools, and itching — in any adult requires urgent evaluation, as obstructive jaundice from bile duct cancer is treatable at early stages. PSC patients who develop worsening jaundice, new right upper quadrant pain, fever, or a rising CA 19-9 trend on surveillance require urgent imaging — CCA developing on PSC demands swift diagnosis to identify resectable disease. Unexplained weight loss, fatigue, or persistent right-sided abdominal pain in individuals with chronic liver disease, hepatitis, or history of bile duct anomalies should prompt hepatobiliary assessment. Any suspicious bile duct stricture or hepatic mass discovered incidentally on imaging requires specialist hepatobiliary evaluation to exclude malignancy. Charcot's triad (fever, jaundice, and right upper quadrant pain) requires urgent emergency evaluation to exclude cholangitis.